LEADERSHIP

Leading the way to a better tomorrow

Sequenom’s executive team of innovative, highly experienced leaders brings a balance of operational, financial, and scientific expertise that positions the company on a trajectory for success.

DIRK VAN DEN BOOM, PhD

President & CEO

Dr. van den Boom serves as the President and CEO. He joined Sequenom in 1998 in the company's Hamburg offices, and previously served in various management roles within the Sequenom R&D department. Prior to his appointment as the CEO, he was the company's Chief Scientific and Strategy Officer. Dr. van den Boom received his PhD in biochemistry/molecular biology from the University of Hamburg where he focused on various aspects of nucleic acid analysis with mass spectrometry. Dr. van den Boom has co-authored more than 50 scientific articles and is inventor on 48 patents/patent applications.

CAROLYN D. BEAVER

Senior Vice President & Chief Financial Officer

Ms. Beaver serves as Senior Vice President and Chief Financial Officer, previously serving as Vice President and Chief Accounting Officer. Prior to joining Sequenom, Ms. Beaver was employed with Beckman Coulter, Inc., a global biomedical testing manufacturer (now a subsidiary of Danaher Corporation) where she served as Corporate Vice President, Controller, and Chief Accounting Officer until 2011. From 1987 until 2002, Ms. Beaver was a partner with KPMG LLP. Ms. Beaver received her Bachelor of Science degree in business administration with an emphasis in accounting from California State Polytechnic University, Pomona and is a licensed CPA.

JEFFREY D. LINTON

Senior Vice President, General Counsel & Secretary

Mr. Linton serves as Senior Vice President, General Counsel and Secretary. Prior to joining Sequenom, Mr. Linton was Senior Vice President and General Counsel at Beckman Coulter, Inc. Prior to that, he was Vice President, Deputy General Counsel. Before joining Beckman Coulter, Mr. Linton was President of the research products and services division of Serologicals Corporation, a company that developed, manufactured and sold life science research products and technologies, diagnostic kits, and drug discovery services. Before that role, Mr. Linton served as Vice President, Corporate Business Development and General Counsel at Serologicals. He has held various other positions in law, government and public affairs, and human resources. Mr. Linton earned a Bachelor of Arts degree from Butler University and a Juris Doctorate degree from the University of Notre Dame Law School.

DANIEL S. GROSU, MD

Senior Vice President & Chief Medical Officer

Dr. Grosu serves as Senior Vice President and Chief Medical Officer. Prior to joining Sequenom, Dr. Grosu served as Illumina’s first Chief Medical Officer and subsequently as the Vice President of Clinical Development and Medical Affairs. He established the Clinical Development and Medical Affairs functions at Illumina, and led the team that performed the clinical studies supporting the FDA clearance and CE marking of the MiSeqDx NGS platform. Prior to joining Illumina, Dr. Grosu held positions of increasing responsibility in the medical diagnostics space at Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Ortho Clinical Diagnostics (a Johnson & Johnson company at the time). Dr. Grosu holds an MD (with Distinction in Research) from Saint Louis University School of Medicine and an MBA from the University of Oxford.

ROBIN WEINER

Senior Vice President, Corporate Governance and Regulatory Affairs

Ms. Weiner serves as Senior Vice President, Corporate Governance and Regulatory Affairs. Prior to joining Sequenom, Ms. Weiner was an independent regulatory consultant to biotechnology companies, focusing on regulatory strategy, product submissions, and quality management systems. From 2004 to 2007, Ms. Weiner served as Vice President Regulatory and Government Affairs at Biosite Incorporated, leading Biosite’s worldwide product approvals and regulatory compliance activities. Prior to Biosite, Ms. Weiner worked for Quidel Corporation, most recently serving as Vice President, Clinical and Regulatory Affairs. Prior to joining Quidel, she held research positions at the Scripps Clinic and Research Foundation and the University of California, San Diego. Ms. Weiner received her MBA from National University and a Bachelor of Arts degree in biology from the University of California, San Diego and is currently on the board of Seacrest Foundation.

MATHIAS EHRICH, MD

Senior Vice President & Chief Scientific Officer

Dr. Ehrich is Sr. Vice President and Chief Scientific Officer at Sequenom, Inc. He joined Sequenom in 2001 in the company’s Hamburg offices and subsequently served in various scientific and management roles within the Sequenom R&D department. His contributions include the development of a high throughput quantitative DNA methylation analysis method, as well as the development of the first-of-its-kind noninvasive prenatal test for fetal chromosomal abnormalities. Before joining Sequenom, Dr. Ehrich worked as a resident in the neonatal intensive care unit in the Children’s Hospital of Altona, Hamburg. He has authored or co-authored numerous peer-reviewed publications on the topic of noninvasive prenatal screening for fetal chromosomal abnormalities and holds 13 patents in the area of genetics. He received his Doctor of Medicine (MD) degree from the University of Hamburg in Germany.

ROB LOZUK

Senior Vice President, Commercial Operations 

Rob Lozuk serves as Senior Vice President, Commercial Operations, providing leadership to the global sales team and overseeing marketing and laboratory operations. Prior to joining Sequenom in 2012 as Vice President, Commercial Operations, Mr. Lozuk was Director of Business Development, Director of Advanced Staining Operations, and Director of Business Development and Americas Marketing for Thermo Fisher Scientific, having served as Director of Sales and Marketing for Fisher Scientific before its merger with Thermo Electron. Prior to his tenure at Thermo Fisher Scientific, Mr. Lozuk had positions of increasing responsibility within the commercial and research and development organizations at Dako (Agilent). He has a wealth of experience in general management, operations, international business, mergers and acquisitions, strategy, and sales and marketing leadership. He holds a degree from the University of California, Santa Barbara.



Board of directors

In a field as rapidly evolving as genomics, staying ahead requires exceptional vision as well as strategic and scientific acumen. Sequenom's Board of Directors is an acclaimed and diverse group of thought leaders representing some of the finest minds in the industry.

KENNETH F. BUECHLER, PhD

+

Dr. Buechler currently serves as the Chairman of the Board of Directors and has served as a director since 2009. He was President, Chief Scientific Officer, and co-founder of Biosite Incorporated. From 1988 to 1994, Dr. Buechler was Biosite's Director of Chemistry. Prior to co-founding Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Incorporated. Dr. Buechler received his PhD in biochemistry and his bachelor’s degree in chemistry from Indiana University. Dr. Buechler is also a director of Quidel Corp., Sotera Wireless, Inc., and Astute Medical Inc.

Dr. Lai-Goldman has served as a director since 2012. She is a managing partner at Personalized Science, LLC, Chief Executive Officer of GeneCentric Diagnostics, Inc., and a venture partner with Hatteras Venture Partners. She previously served as Executive Vice President, Chief Medical Officer, and Chief Scientific Officer of Laboratory Corporation of America. Dr. Lai-Goldman received her MD degree from Columbia University and an undergraduate degree in biology from the University of Pennsylvania. She completed a pathology residency and surgical pathology fellowship at University of California, Los Angeles, followed by a hematopathology fellowship at the University of North Carolina at Chapel Hill.

Dr. Lerner has served as a director since 2007. Dr. Lerner is the former President of the Scripps Research Institute, a private, non-profit biomedical research organization, having served since 1986. Dr. Lerner received the Wolf Prize in Chemistry in 1994, the California Scientist of the Year Award in 1996, the Paul Ehrlich and Ludwig Darmstaedter Prize in 2003, and the Prince of Asturias Award in 2012 for his achievements in the development of catalytic antibodies and combinatorial antibody libraries. Dr. Lerner is a member of the Royal Swedish Academy of Sciences and the National Academy of Sciences. Dr. Lerner currently serves as a director of Kraft Foods, Inc., Opko Health, Inc., Xencor, Inc., and Intra-Cellular Therapies. Dr. Lerner received his MD degree from Stanford Medical School.

Dr. Lindsay has served as a director since 2003. Dr. Lindsay previously served as Executive Vice President, Strategic Planning, and as Executive Vice President of Research and Development. Prior to joining Sequenom, Dr. Lindsay served as Vice President, Research and Development, and Chief Science Officer of diaDexus, Inc., a biotechnology company, from 2000 to January 2004. From 1997 through 2000, Dr. Lindsay served in various senior management roles with Millennium Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 to 1997, Dr. Lindsay served in various roles with Regeneron Pharmaceuticals, Inc., of which he was a founding scientist. He is also a director of Arqule, Inc. Dr. Lindsay received his PhD in biochemistry from the University of Calgary.

Mr. Pendarvis has served as a director since 2009. He currently serves as the Chief Administrative Officer and Global General Counsel of ResMed, Inc., a medical device company focused on sleep-disordered breathing. From 2000 until 2002, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware & Freidenrich LLP. From 1986 until 2000, he was a partner with Gibson, Dunn & Crutcher LLP. From 1984 until 1986, he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Mr. Pendarvis received his JD from the University of Texas School of Law, an MS in executive leadership from the University of San Diego, and a BA from Rice University.

Dr. Mackey has served as a director since June 2015. She is the Chief Executive Officer of CYPrus Therapeutics, Inc., Chairman of the Board of Directors of Cour Pharma, and a member of the Board of Directors of Viventia Bio, Inc. and Evolve Biosystems, Inc. She serves as an Advisor to Fortis Advisors, FHOOSH, Inc., and Cypher Genomics. In addition, Dr. Mackey is a member of the Board of Trustees of Rady Children’s Hospital and is past-chair of CONNECT. Dr. Mackey was Sr. VP of Global R&D, Pfizer, Inc from 2001 through 2010. Prior to that, she held executive positions at Pfizer, as head of Strategic Alliances and Genomic and Proteomic Sciences, and at Monsanto and DEKALB Genetics. Dr. Mackey received her B.S. and Ph.D. degrees in microbiology from Cornell University.

Mr. Slacik has served as a director since 2012. He had previously served as Chief Financial Officer and Senior Vice President of Finance for Beckman Coulter (now a subsidiary of Danaher Corporation) where he was responsible for all aspects of financial management and information technology. Prior to joining Beckman Coulter, Mr. Slacik was Executive Vice President and Chief Financial Officer at Watson Pharmaceuticals, a specialty pharmaceutical company in Corona, California. Before that, he served as Senior Vice President and Chief Financial Officer at C.R. Bard, Inc., a developer and manufacturer of medical technologies in the fields of vascular, urology, oncology, and surgical specialty products. Mr. Slacik received his BS degree in accounting and finance from the University of Connecticut and is a certified public accountant. He is currently a member of the Orange County Chapter of Financial Executives International and the Connecticut Society of CPAs. Mr. Slacik currently serves as a director of STAAR Surgical Company.

Dr. van den Boom serves as the President and Chief Executive Officer and as a director. He previously served as Executive Vice President, Chief Scientific and Strategy Officer. From October 2009 until December 2012, he led the research and development function as Vice President and then Senior Vice President. He joined Sequenom in 1998 in the company’s Hamburg offices, serving in various management roles within the Sequenom R&D department. Dr. van den Boom received his PhD in biochemistry/molecular biology from the University of Hamburg where he focused on various aspects of nucleic acid analysis with mass spectrometry. Dr. van den Boom has co-authored more than 80 scientific articles and is inventor on 48 patents/patent applications.